AALL1521; Ruxolitinib and Chemotherapy for Patients with JAK-Mutant B-ALL

This study is testing the safety and effectiveness of adding a targeted therapy (ruxolitinib) to standard chemotherapy for children, adolescents, and young adults with high-risk acute lymphoblastic leukemia with CRLF2 and other JAK pathway mutations.